Azitra Inc ((AZTR)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Azitra Inc. is conducting a study titled ‘A Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity.’ The study aims to assess the safety and efficacy of ATR04-484, a topical treatment for skin rashes in patients undergoing EGFR inhibitor therapy. This research is significant as it seeks to address common side effects of cancer treatments, potentially improving patient quality of life.
The intervention being tested is ATR04-484, a recombinant live biotherapeutic product applied topically. It contains an engineered strain of S. epidermidis and is intended to treat skin rashes associated with EGFR inhibitor therapy.
The study is designed as a randomized, double-blind, vehicle-controlled trial with a parallel intervention model. It involves quadruple masking to ensure unbiased results, focusing primarily on treatment outcomes.
The study began on February 12, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on September 3, 2025, indicating ongoing recruitment and progress.
This update could positively impact Azitra Inc.’s stock performance by showcasing their commitment to innovative treatments, potentially boosting investor confidence. As the study progresses, it may also influence the competitive landscape, particularly among companies developing dermatological solutions for cancer therapy side effects.
The study is currently ongoing, with further details available on the ClinicalTrials portal.